Tratamiento citorreductor disponible en Colombia para la trombocitemia esencial. Revisión panorámica de la evidencia

Essential thrombocythemia (ET) is a BCR-ABL negative chronic myeloproliferative neoplasm, characterized by excessive production of clonal platelets. The worldwide prevalence varies, being approximately 38 to 57 per 100,000. Treatment of ET is aimed at reducing the risk of thrombosis or bleeding complications. Aim: The purpose of this panoramic review is to evaluate the current evidence on the cytoreductive treatment of essential thrombocythemia available in Colombia. Methods: A structured literature search was carried out regarding the effectiveness and safety of cytoreductive treatments in patients with essential thrombocythemia. Based on the research question with a PICO structure, the inclusion criteria were defined: Patients with essential thrombocythemia, under management with Anagrelide and/or Hydroxyurea. Studies from systematic reviews, meta-analyses, randomized clinical trials were included. Results: A search was carried out in MEDLINE, EMBASE, LILACS, Cochrane Database of Systematic Reviews, which yielded 119 references, of which 4 studies were included, which met the characteristics of the population, intervention, and comparator. Conclusions: Cytoreductive therapy is essential for the management of Essential Thrombocythemia. Evidence suggests that both Hydroxyurea and Anangrelide are agents that provide similar protection against clinically significant thrombo-hemorrhagic events.